Navigation Links
Data to be Presented at ASCO 2007 Highlights sanofi-aventis,Commitment to Cancer Care and Research

cancer in the developing world will be presented in this presentation. -- Sunday, June 3, 2:00 PM - 6:00 PM, S Hall A2, Poster Number W2. About Eloxatin(R) Indications and Usage

Eloxatin(R) (oxaliplatin for injection), a DACH platinum, is approved in combination with infusional 5-FU/LV for the second-line treatment of patients with advanced carcinoma of the colon or rectum. In 2004, Eloxatin received additional approval for the first-line treatment of these patients. Based on data showing improvement in disease-free survival, Eloxatin was also approved in 2004 for use in combination with infusional 5-FU/LV in adjuvant (post- surgery) treatment of stage III colon cancer patients.

Clinical Safety Considerations

Eloxatin(R) should be administered under the supervision of a physician experienced in the use of cancer chemotherapeutic agents.

Appropriate management of therapy and complications is possible only when adequate diagnostic and treatment facilities are readily available.

Anaphylactic-like reactions to Eloxatin(R) have been reported and may occur within minutes of Eloxatin(R) administration. Epinephrine, corticosteroids, and antihistamines have been employed to alleviate symptoms, and discontinuation of Eloxatin(R) therapy may be required.


    -- Eloxatin(R) should not be administered to patients with a history of

       known allergy to Eloxatin(R) or other platinum compounds.

       Hypersensitivity and anaphylactic/anaphylactoid reactions to

       Eloxatin(R) have been reported and were similar in nature and severity

       to those reported with other platinum compounds (ie, rash, urticaria,

       erythema, pruritus, and, rarely, bronchospasm and hypotension). These

       reactions occur within minutes of administration and should be managed

       with appropriate supportive therapy. Drug-related deaths from this

       reaction have been reported


    -- Eloxatin(R) may cause fet
'"/>




Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related medicine technology :

1. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
2. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
3. Positive ZIO-201 Interim Phase II Sarcoma Data Presented at European Society for Medical Oncology
4. Clinical Data From Nymox BPH Drug To Be Presented at American Urological Association Meeting
5. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
6. ZIO-101 (Darinaparsin) Interim Phase II and Preclinical Data Presented at International Myeloma Workshop
7. Nymox Announces NX-1207 Data to Be Presented at Upcoming U.S. Urology Meetings
8. MEDIA ADVISORY: Subsets of Landmark Diabetes Trials Investigating MacroVascular Outcomes Presented at the American Diabetes Association 67th Scientific Sessions
9. Nymox Announces NX-1207 Data to Be Presented at Upcoming U.S. Urology Meetings
10. ConjuChem Biotechnologies Reports PC-DAC:Exendin-4 Albumin Conjugate Data Presented at American Diabetes Association Annual Meeting
11. New Data Presented on Micardis (Telmisartan) Tablets in Hypertensive Patients With Type 2 Diabetes
Post Your Comments:
(Date:9/19/2014)... Sept. 19, 2014 "Copay coupons," ... sales of brand drugs among patients with prescription drug ... to a new report  from the Department ... Inspector General (OIG). Federal anti-kickback laws prohibit suppliers ... are subsidized by the federal government. ...
(Date:9/19/2014)... , Sept. 19, 2014 /PRNewswire-iReach/ -- ... to 2020″, provides key market data ... devices market. The report provides value, ... volume (in units) within market categories ... Sigmoidoscopes, Esophagoscopes & Gastroscopes, Duodenoscopes, Laparoscopes, ...
(Date:9/19/2014)... 2014 According to the ... Heat, therapy, Hydrotherapy), Accessories (Posture Mirror, Exercise Ball), Applications ... - Global Forecast to 2019" published by MarketsandMarkets, the ... $19,786.3 Million by 2019 from $14,240.0 Million in ... to 2019. Browse 74 market data ...
Breaking Medicine Technology:PCMA: New OIG Report Cites Drug Manufacturer "Copay Coupon" Use in Medicare Part D 2United States General Surgery Devices Market to 2020 - Endoscopy, Bariatric Surgery, Aesthetic Lasers and Energy, Biopsy Devices, Hernia Repair, Non-Vascular Stents 2United States General Surgery Devices Market to 2020 - Endoscopy, Bariatric Surgery, Aesthetic Lasers and Energy, Biopsy Devices, Hernia Repair, Non-Vascular Stents 3United States General Surgery Devices Market to 2020 - Endoscopy, Bariatric Surgery, Aesthetic Lasers and Energy, Biopsy Devices, Hernia Repair, Non-Vascular Stents 4United States General Surgery Devices Market to 2020 - Endoscopy, Bariatric Surgery, Aesthetic Lasers and Energy, Biopsy Devices, Hernia Repair, Non-Vascular Stents 5Physiotherapy Equipment Market Worth $19,786.3 Million by 2019 2Physiotherapy Equipment Market Worth $19,786.3 Million by 2019 3Physiotherapy Equipment Market Worth $19,786.3 Million by 2019 4
... SphygmoCor system plays key role in discovery, ... A,new study of more than 10,000 patients, conducted ... United Kingdom using AtCor Medical Holdings,Limited,s SphygmoCor(R) has ... as having "high normal" systolic blood pressure through,traditional ...
... 28 ACCESS PHARMACEUTICALS, INC.,(OTC Bulletin Board: ... oral and,poster presentations on its Cobalamin(TM) technology ... to Clinical Practice, taking,place from May 26-28 ... B12-Polymer Conjugates as Constructs for Targeted Tumor ...
Cached Medicine Technology:New Study Linking 'High Normal' Blood Pressure to Significant Cardiovascular Risk 2New Study Linking 'High Normal' Blood Pressure to Significant Cardiovascular Risk 3Access Pharmaceuticals Presents New Data on the Company's Cobalamin(TM) Technology at an International Polymer Therapeutics Symposium 2Access Pharmaceuticals Presents New Data on the Company's Cobalamin(TM) Technology at an International Polymer Therapeutics Symposium 3
(Date:9/21/2014)... CareSpan USA, Inc. announced today at the ... services agreement with Avera eCARE, a leading healthcare system ... Clinic in multiple states where Avera eCARE is licensed. ... joint services in remote and rural parts of North ... licensed. The two companies’ strategy is to focus on ...
(Date:9/21/2014)... Dallas, Texas (PRWEB) September 22, 2014 ... was originally launched in 1997, and is used ... children and adults. Its active ingredient, budesonide, is ... the corticosteroid receptor. AstraZeneca’s Pulmicort franchise includes the ... older than six years of age, Pulmicort Respules ...
(Date:9/21/2014)... an allergy to peanuts than raw peanuts, suggests an ... that specific chemical changes caused by the high temperatures ... body,s immune system, ,priming, the body to set off ... any peanuts. , The results might explain the difference ... the Western world compared to populations in East Asia, ...
(Date:9/21/2014)... York, NY (PRWEB) September 21, 2014 ... enabled more generic drugs to inundate the market, thereby ... Pharmaceutical Manufacturing industry. According to data from Industry ... has cost the industry $1.8 and $2.5 billion in ... brand-name drugs losing patent exclusivity, which has hampered revenue ...
(Date:9/21/2014)... "I want to help people who ... haven’t the money for chiropractors," said an inventor from ... a product for myself." , The Stretch is a ... thigh muscles and align the spine properly. It improves ... of pinched nerves. Compact and easy to use, it's ...
Breaking Medicine News(10 mins):Health News:Avera eCARE and CareSpan form Collaboration to Deliver “Virtualized” Primary Care in the Dakotas and Wyoming 2Health News:Avera eCARE and CareSpan form Collaboration to Deliver “Virtualized” Primary Care in the Dakotas and Wyoming 3Health News:Pulmicort Asthma Market (Epidemiology, Etiology, Symptoms, Diagnosis, Pathology) Forecasts to 2023 in New Report Available at LifeScienceIndustryResearch.com 2Health News:Pulmicort Asthma Market (Epidemiology, Etiology, Symptoms, Diagnosis, Pathology) Forecasts to 2023 in New Report Available at LifeScienceIndustryResearch.com 3Health News:Pulmicort Asthma Market (Epidemiology, Etiology, Symptoms, Diagnosis, Pathology) Forecasts to 2023 in New Report Available at LifeScienceIndustryResearch.com 4Health News:Dry roasting could help trigger peanut allergy 2Health News:Brand Name Pharmaceutical Manufacturing in Canada Industry Market Research Report Now Available from IBISWorld 2Health News:Brand Name Pharmaceutical Manufacturing in Canada Industry Market Research Report Now Available from IBISWorld 3
... decade since the U.S. Food and Drug Administration approved the ... But several insurance companies still deny coverage, Loyola University ... FootForum commentary in Foot & Ankle International , the ... "It seems curious that the FDA agrees with the ...
... French . , Montreal, June 4th, 2009 ... a disease that results in severe breathing difficulty. According to ... worldwide. However the mechanisms responsible for some smokers developing COPD ... Dr.Manuel Cosio from the McGill University Health Centre, ...
... to Provide Networking Tips In-Person at Six Club Health Club ... Premier health clubs, The Sports Club/LA and ... Management, have teamed up with leading business social networking site ... to strengthen job prospects and health. The educational and ...
... Video discusses the American Recovery & Reinvestment Act, Electronic Health ... June 4 Perot Systems Corporation (NYSE: PER ... of its latest Webcast, "The Impact of The U.S. Stimulus ... programs for the healthcare industry. , , To access ...
... Gift That Does Wonders For His Skin , , ... Calif., June 4 Forget ties and cologne for Father,s ... may not buy for himself: An Anti-Wrinkle Moisturizer -- and ... Physician-Formulated Anti-Wrinkle Moisturizer is an all-in-one cream ...
... 4 Alaska Governor Sarah Palin, named "2009 Honoree" by ... ), will be honored before a sold out crowd ... gala on Sunday, June 7(th) at Flowerfields in St. James. ... on Long Island. Independent Group Home Living (IGHL; ...
Cached Medicine News:Health News:The FDA has approved ankle replacements, so why don't all insurance plans cover them? 2Health News:Investigation finds that cigarette smoking does not affect everyone in same way 2Health News:The Sports Club/LA and Reebok Sports Club/NY Team Up With LinkedIn to Host a Series of Networking Events Strengthening Career and Well-Being 2Health News:The Sports Club/LA and Reebok Sports Club/NY Team Up With LinkedIn to Host a Series of Networking Events Strengthening Career and Well-Being 3Health News:The Sports Club/LA and Reebok Sports Club/NY Team Up With LinkedIn to Host a Series of Networking Events Strengthening Career and Well-Being 4Health News:Perot Systems Releases ARRA Webcast Featuring Leading Analyst Firm 2Health News:Perot Systems Releases ARRA Webcast Featuring Leading Analyst Firm 3Health News:SHOW DAD YOU LOVE HIS FACE 2Health News:Alaska Governor Sarah Palin to be Honored Before Sold Out Crowd at IGHL 30(th) Anniversary Gala During First Visit to Long Island 2
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: